ARCS Honolulu Chapter invites you
to a free Pau Hana hybrid talk on Thursday Oct. 8

Ebola Vaccine Development During a Public Health Emergency and Implications for Pandemic Preparedness

Featuring Dr. Beth-Ann Griswold Coller

UH Mānoa John A. Burns School of Medicine

Medical Education Building
651 Ilalo Street, Honolulu

Thursday, Oct. 8
Pupus from 5:30 p.m.
Zoom open from 5:45 p.m.
Talk begins at 6 p.m.

RSVP Required

By Oct. 1 for in-person
or Oct. 7 for online access
https://tinyurl.com/ARCS-Ebola
or email arcshonolulu@gmail.com

About the Speaker

Retired pharmaceutical executive **Beth-Ann Coller** has more than 30 years in vaccine development, most recently leading work on Ebola and dengue vaccines at MERCK. She is an advisor to the Coalition for Epidemic Preparedness Innovation, a global organization working to accelerate vaccine development. She also leads updates to WHO's Filovirus Road Map and serves on two NIH program advisory boards and a data-monitoring committee for a nonprofit involved in Filovirus vaccine development.

ARCS ADVANCING SCIENCE IN AMERICA®

ARCS Foundation supports outstanding graduate students in STEM and health disciplines to keep the U.S. competitive in science and technology. The **Honolulu Chapter** has provided more than $2.8 million to nearly 700 University of Hawai'i at Manoa doctoral students. Learn more at **Honolulu.arcsfoundation.org**

The expanding, uncontrolled Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo threatens to be the largest Ebola outbreak in history. The World Health Organization has declared it a Public Health Emergency of International Concern.

Join us for an overview of key innovations in the development of an Ebolavirus vaccine, how that knowledge is being applied to the current outbreak, and how Ebola research being conducted at JABSOM is contributing to outbreak response.

Development of vaccines and therapeutics is essential for long-term prevention and control of Ebolaviruses. Development of ERVEBO—the licensed single-dose, live-attenuated recombinant vaccine for the Zaire strain of Ebolavirus—provides important lessons on the regulatory, clinical, and development process that can be applied to the ongoing Bundibugyo outbreak and other epidemic pathogens. These lessons include the critical nature of public-private partnerships, need for innovation and coordination in clinical trial design, regulatory harmonization, and importance of community engagement.

Applying this knowledge is key as the public health community comes together to address the Bundibugyo outbreak, especially given reduced investment in emerging infectious disease research and the U.S. withdrawal from the WHO.



Parking in metered stalls on Ilalo and Cook Streets
or Lot C ($2 per hour, cashless payment only)
Directions and parking info at https://go.hawaii.edu/p9R